Genentech, a member of the Roche Group, along with the Breast International Group, Breast European Adjuvant Study Team and Frontier Science Foundation, recently announced positive results from the Phase III Aphinity study for Perjeta and Herceptin-based adjuvant treatment in combating breast cancer.
“The goal of adjuvant treatment is to help each person with cancer have the best chance of a cure, and we come closer to this goal with each advance,” Dr. Sandra Horning, Genentech's chief medical officer and head of Global Product Development, said in a statement. “In the Aphinity study, the Perjeta-based regimen improved upon the high bar set by Herceptin in people with HER2-positive early breast cancer. We look forward to working with global health authorities to bring this treatment option to patients.”
In the study, the adjuvant treatment, in combination with Perjeta (pertuzumab) and Herceptin (trastuzumab), along with chemotherapy (the Perjeta-based regimen), delivered a reduction in the risk of breast cancer recurrence or death in the involved patients.
“Aphinity provides yet another example of the importance of industry-academic collaborations and their value in advancing cancer care for people affected by this challenging disease,” study coordinator Dr. Gunter von Minckwitz said. “The median follow-up at the primary analysis was 45.4 months, and these early data are very encouraging. As we continue to follow patients up to 10 years, we hope that future analyses will provide additional insights on the role of a pertuzumab-based regimen in HER2-positive early breast cancer.”
Alerts Sign-up